{"entity":{"id":"nct05307705","kind":"trial","name":"LOXO-783 in breast cancer and other solid tumors","aka":["A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors"],"tldr":"This early study tests LOXO-783 alone and with other cancer treatments in tumors with selected PIK3CA gene changes. It looks at safety, dose and early treatment activity.","summary":"This early study tests LOXO-783 alone and with other cancer treatments in tumors with selected PIK3CA gene changes. It looks at safety, dose and early treatment activity.\n\nInterventional study registered as NCT05307705, sponsored by Eli Lilly and Company. Registry phase: 1. Registry enrollment is 260 participants (estimated). Registry status checked October 10, 2026: recruiting. UCSF lists this study as open to eligible people; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"recruiting","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT05307705","url":"https://clinicaltrials.gov/study/NCT05307705"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT05307705"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["abemaciclib","fulvestrant","imlunestrant","paclitaxel"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05307705","phase":"1","setting":"Breast cancer and other solid tumors with selected PIK3CA alterations","sponsor":"Eli Lilly and Company","participation":[{"nct":"NCT05307705","source":"https://clinicaltrials.gov/study/NCT05307705","fetchedAt":"2026-10-10T20:54:18.777694Z","studySha256":"533a300434ca82aa8b4b9b13805e04759f348878d23a4eafceef25669809966f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-08","leadSponsor":"Eli Lilly and Company","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":260,"enrolmentType":"ESTIMATED","siteCount":50,"recruitingSiteCount":17,"countries":["Australia","Belgium","Canada","China","France","Germany","Japan","Singapore","South Korea","Spain","United Kingdom","United States"]}],"started":"2022-05-11","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05307705/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"},{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"},{"id":"imlunestrant","kind":"drug","name":"Imlunestrant","route":"/drugs/imlunestrant/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}